GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

OBI Pharma’s product and technology portfolio focuses on antibody-drug conjugates (ADCs) and enabling platforms. Core proprietary technologies include GlycOBI® glycan-conjugation platform, EndoSymeOBI®, ThiOBI®, HYPrOBI™, which enable plug-and-play compat

Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit

ANG-NeoSync® Innovative Immune Cell Therapy Platform. DC/T cell products, comprehensively targeting tumor neoantigens. Patented tumor neoantigen mRNA, enabling personalized and precise targeting for immune cell therapy. Specific tumor therapy, delivering superior efficacy and safety.

Product Development:
1. AGT-NeoAgs panel: First, whole-genome sequencing is performed to obtain mutation information from the tumor, identifying potential neoantigen targets. Based on these customized targets, neoantigen mRNA vaccines are synthesized to be used for the subsequent training of cell products. Concurrently, the patient's immune cells are collected, and dendritic cells (DCs) and T cells are isolated for the preparation of NeoPrime® DC and NeoBoost® T-cells.
2. AGT-NeoPrime® DC: NeoPrime® DC is the tumor neoantigen-specific DC produced by AngenMed Therapeutics INC. DCs act as the "teachers" of T cells. After being isolated from the patient's immune cells, they are introduced to the neoantigen mRNA vaccine for DC differentiation training and cultivation. Through antigen presentation, the DCs express these "teaching materials" to subsequently train T cells to recognize cancer targets.
3. AGT-NeoBoost® T-cells: T cells isolated from white blood cells are co-cultured with NeoPrime® DC to expand tumor neoantigen-specific T cells, yielding the final NeoBoost® T-cells product. Having been trained by the neoantigen-specific DCs, these T cells acquire tumor-recognition capabilities and can be expanded by more than 100-fold. Acting like a massive arsenal of specific anti-cancer weapons assembled in vitro, they precisely eradicate tumor cells.